Biomarkers of Renal Diseases

• Format: eBook
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Subjects: Medicine and Nursing; acute kidney injury; acute rejection; acute tubulointerstitial nephritis; antibody-mediated rejection; arterial hypertension; biomarker; biomarkers; calcineurin-inhibitor nephrotoxicity; cardiovascular disease; chronic allograft dysfunction; chronic kidney disease; chronic rejection; CKD; cystatin C; cystatin-C; diabetic kidney disease; diagnostic test accuracy; differential diagnosis; end-stage kidney disease (ESKD); epidemiology; exercise; extracellular vesicles; functional assessment; furosemide stress test; gentamicin; immunology; immunosuppression; infection-related glomerulonephritis; kidney function; kidney graft; kidney graft function; kidney injury; kidney injury molecule 1; kidney transplantation; KIM-1; label-free quantification; long noncoding RNA; machine learning; macrophage subpopulation; markers of AKI; mass spectrometry; microRNA; microvascular injury; miRNA; monocyte chemotactic protein-1; n/a; nephritis-associated plasmin receptor; nephrotoxicity; neutrophil gelatinase-associated lipocalin; NGAL; plasmin; Polyomavirus associated nephropathy; poststreptococcal acute glomerulonephritis; proteomics; rejection; renal biomarkers; renal fibrosis; renal function; renal transplant; sepsis; statistical clinical model; T-cell-mediated rejection; trichostatin A; upper urinary tract obstruction; urinary aminopeptidases; urinary biomarkers; urine; uromodulin; vancomycin; vanin-1
• Online Access: Open Access: DOAB: description of the publication; Open Access: DOAB, download the publication
• Physical Description: 1 online resource (276 p.)
• ISBN: 9783039439119; 9783039439126; books978-3-03943-912-6
• Access: Open Access

This book provides important and updated information on current research devoted to urinary biomarkers. Urinary biomarkers are characteristics that can be objectively measured and evaluated as indicators of normal biological or pathogenic processes of pharmacological responses to therapeutic intervention.